IL266399B2 - Synthetic chimeric poxviruses, methods for producing same, compositions comprising same and uses thereof - Google Patents

Synthetic chimeric poxviruses, methods for producing same, compositions comprising same and uses thereof

Info

Publication number
IL266399B2
IL266399B2 IL266399A IL26639919A IL266399B2 IL 266399 B2 IL266399 B2 IL 266399B2 IL 266399 A IL266399 A IL 266399A IL 26639919 A IL26639919 A IL 26639919A IL 266399 B2 IL266399 B2 IL 266399B2
Authority
IL
Israel
Prior art keywords
virus
scopv
genome
vacv
schpxv
Prior art date
Application number
IL266399A
Other languages
English (en)
Hebrew (he)
Other versions
IL266399A (en
IL266399B1 (en
Original Assignee
Evans David
Noyce Ryan
Lederman Seth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evans David, Noyce Ryan, Lederman Seth filed Critical Evans David
Publication of IL266399A publication Critical patent/IL266399A/en
Publication of IL266399B1 publication Critical patent/IL266399B1/en
Publication of IL266399B2 publication Critical patent/IL266399B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL266399A 2016-11-02 2017-11-02 Synthetic chimeric poxviruses, methods for producing same, compositions comprising same and uses thereof IL266399B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416577P 2016-11-02 2016-11-02
US201662434794P 2016-12-15 2016-12-15
PCT/US2017/059782 WO2018085582A1 (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses

Publications (3)

Publication Number Publication Date
IL266399A IL266399A (en) 2019-06-30
IL266399B1 IL266399B1 (en) 2025-05-01
IL266399B2 true IL266399B2 (en) 2025-09-01

Family

ID=62075555

Family Applications (2)

Application Number Title Priority Date Filing Date
IL319942A IL319942A (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof
IL266399A IL266399B2 (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses, methods for producing same, compositions comprising same and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL319942A IL319942A (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof

Country Status (14)

Country Link
US (2) US11345896B2 (OSRAM)
EP (1) EP3535389A4 (OSRAM)
JP (3) JP2019535311A (OSRAM)
CN (1) CN110431228B (OSRAM)
AU (2) AU2017353868C1 (OSRAM)
BR (1) BR112019008781A2 (OSRAM)
CA (1) CA3042694A1 (OSRAM)
IL (2) IL319942A (OSRAM)
MX (1) MX2019005102A (OSRAM)
NZ (1) NZ752893A (OSRAM)
SG (1) SG11201903893PA (OSRAM)
TW (2) TW202528334A (OSRAM)
WO (1) WO2018085582A1 (OSRAM)
ZA (3) ZA201902868B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085582A1 (en) 2016-11-02 2018-05-11 David Evans Synthetic chimeric poxviruses
US20180228921A1 (en) * 2017-02-13 2018-08-16 Excision Biotherapeutics, Inc. Visualizing viral reservoirs and dissemination in vivo
EP3788142A4 (en) * 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS
US20240024393A1 (en) * 2019-01-25 2024-01-25 Virocure, Inc. Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus
US20230097513A1 (en) * 2020-02-03 2023-03-30 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
EP4110386A1 (en) * 2020-02-26 2023-01-04 Tonix Pharma Limited Recombinant poxvirus based vaccine against sars-cov-2 virus
MX2023009008A (es) 2021-02-02 2023-10-05 Geovax Inc Constructos virales para usarse en potenciar el cebado de linfocitos t durante la vacunación.
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN117264909B (zh) * 2023-10-25 2024-11-26 深圳湾实验室 反式互补缺陷猴痘病毒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US20070275010A1 (en) 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
WO2006022215A1 (ja) 2004-08-23 2006-03-02 The Japan Health Sciences Foundation SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
FI20115914A7 (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
ES2768292T3 (es) 2013-04-10 2020-06-22 Tot Shanghai R&D Center Co Ltd Cepas de virus vaccinia mutante, usos de estas y método para producirlas
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
MX393612B (es) 2015-08-11 2025-03-24 Calidi Biotherapeutics Nevada Inc Vacuna contra viruela para tratamiento del cancer.
EP3515419A4 (en) 2016-09-21 2020-06-10 Stephen H. Thorne High mobility group box i mutant
WO2018085582A1 (en) 2016-11-02 2018-05-11 David Evans Synthetic chimeric poxviruses
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
CA3098145A1 (en) 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
EP3788142A4 (en) 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E. R. TULMAN ET AL,, GENOME OF HORSEPOX VIRUS, 15 September 2006 (2006-09-15) *

Also Published As

Publication number Publication date
WO2018085582A1 (en) 2018-05-11
IL266399A (en) 2019-06-30
MX2019005102A (es) 2019-10-30
AU2024200997A1 (en) 2024-03-07
JP2019535311A (ja) 2019-12-12
TW201819400A (zh) 2018-06-01
BR112019008781A2 (pt) 2019-07-16
US20230002741A1 (en) 2023-01-05
US20180251736A1 (en) 2018-09-06
TW202528334A (zh) 2025-07-16
AU2017353868C1 (en) 2024-06-06
US11345896B2 (en) 2022-05-31
EP3535389A4 (en) 2020-06-03
JP2024107257A (ja) 2024-08-08
CA3042694A1 (en) 2018-05-11
CN110431228B (zh) 2024-04-02
IL319942A (en) 2025-05-01
JP2022164900A (ja) 2022-10-27
AU2017353868B2 (en) 2024-02-29
CN110431228A (zh) 2019-11-08
AU2017353868A1 (en) 2019-05-16
EP3535389A1 (en) 2019-09-11
SG11201903893PA (en) 2019-05-30
IL266399B1 (en) 2025-05-01
TWI887191B (zh) 2025-06-21
ZA201902868B (en) 2022-12-21
ZA202204981B (en) 2024-09-25
NZ752893A (en) 2025-10-31
US12365879B2 (en) 2025-07-22
ZA202403393B (en) 2025-08-27

Similar Documents

Publication Publication Date Title
US12365879B2 (en) Synthetic chimeric poxviruses
US20210230560A1 (en) Synthetic chimeric vaccinia virus
WO2021174142A1 (en) Recombinant poxvirus based vaccine against sars-cov-2 virus
US20210236619A1 (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
US20040014034A1 (en) Method of producing a recombinant virus
HK40014109B (zh) 合成嵌合痘病毒
HK40014109A (en) Synthetic chimeric poxviruses
WO2023168286A1 (en) Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
Holley Mechanistic Constraints on the Formation of Virion Morphotypes in Vaccinia Virus
Ríos et al. INVESTIGATION OF POXVIRUS HOST-RANGE AND GENE EXPRESSION IN MAMMALIAN CELLS.
Hu The development of penguinpox virus (PEPV) as a vaccine vector: transfer vector construction and rescue of virus growth in rabbit kidney cells (RK-13) by vaccinia virus K1